We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LDOS:NYSELeidos Holdings, Inc. Analysis

Data as of 2026-03-10 - not real-time

$173.39

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Leidos (LDOS) is trading at $173.38, just below its 20‑day SMA of 175.42 and well under the 50‑day SMA of 184.56, indicating short‑term pressure but still above the key support level of 161.05. The RSI of 44 suggests the stock is not yet oversold, while the MACD histogram is positive (+0.67), giving a modest bullish signal despite a neutral overall trend. Valuation metrics show a trailing PE of 15.6, far below the industry average of 36.9, yet the DCF‑derived fair value of $86.4 is less than half the market price, highlighting a divergence between market expectations and intrinsic estimates. The company delivers a modest dividend yield of 0.92% with a low payout ratio (14.6%), supporting dividend sustainability. High 30‑day volatility at 53.9% and decreasing volume point to elevated short‑term risk, but a low beta of 0.52 tempers market‑wide exposure. Strong fundamentals—ROE of 31%, positive free cash flow, and a solid backlog of defense contracts—provide a resilient earnings base. Analysts maintain a “buy” consensus with a mean target of $212.5, implying ~22% upside, while recent news highlights accelerated migration of Defense Agency workloads to DODNet and successful deployment of the Terminal Flight Data Manager system, underscoring growth catalysts. In summary, LDOS appears fairly valued with upside potential driven by defense and AI initiatives, but short‑term price pressure and high volatility warrant cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMA and decreasing volume
  • Neutral trend with modest bullish MACD histogram
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst price targets implying ~22% upside
  • Strong defense contract pipeline and AI initiatives
  • Low PE relative to industry peers

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained ROE above 30% and positive free cash flow
  • Dividend sustainability with low payout ratio
  • Strategic position in government and commercial security markets

Key Metrics & Analysis

Financial Health

Revenue Growth-3.60%
Profit Margin8.43%
P/E Ratio15.6
ROE31.03%
ROA9.90%
Debt/Equity107.66
P/B Ratio4.5
Op. Cash Flow$1.8B
Free Cash Flow$1.1B
Industry P/E36.9

Technical Analysis

TrendNeutral
RSI44.0
Support$161.05
Resistance$196.00
MA 20$175.42
MA 50$184.56
MA 200$178.23
MACDBullish
VolumeDecreasing
Fear & Greed Index78.09

Valuation

Fair Value$86.42
Target Price$212.46
Upside/Downside22.54%
GradeFair
TypeBlend
Dividend Yield0.92%

Risk Assessment

Beta0.52
Volatility53.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.